The ROAs for the Gene Therapy Consortium were published on December 4, 2023. Please find the links below. The submissions will be accepted starting on December 28, 2023 and the submission deadline is rolling.
- Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 1 Preliminary Application (OT2)
- Ultra-rare Gene-based Therapy (URGenT) Clinical Trials Conducted within NeuroNEXT: Stage 2 Protocol Application (OT2)